Gilead Sciences (NASDAQ:GILD) said it has received FDA Breakthrough Therapy Designation for its antibody-drug conjugate ...
City of Hope scientists have identified a protein, YTHDF2, that helps cancer cells evade CAR T cell therapy. They developed a ...
Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...
AIIMS researchers claim to have made significant progress in developing chimeric antigen receptor (CAR) T-cell therapy, ...
The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting ...
Scientists have discovered a key protein that helps cancer cells avoid detection by the immune system during a type of ...
The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...
The Breakthrough Therapy designation is supported by data from the randomized, open-label phase 2 SOLSTICE trial.
New research has found that stimulant drugs and atomoxetine appear to be the best treatments for adults with ADHD - which is ...
Monroe Carell was a natural fit to offer the new therapy. Its multidisciplinary DMD Clinic, co-directed by Burnette, Soslow ...
Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, tolebrutinib, for treating adults with non-relapsing secondary ...